A combined IgG and IgM antibody panel is available (refer to Chlamydia Antibody Panel, IgG & IgM by IFA (0065100)). Differentiate between Chlamydophila species (C. psittaci, C. pneumoniae). Because of cross-reactivity, a C. pneumoniae-specific reaction will exhibit titers two-fold or greater than C. trachomatis or C. psittaci serology. Limited value in the diagnosis of most oculogenital (eg, eyes, genitalia) chlamydial infections.
Semi-Quantitative Indirect Fluorescent Antibody
Plain red or serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as acute or convalescent.
Contaminated, hemolyzed, or hyperlipemic sera.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
< 1:64 C. trachomatis IgG.
< 1:64 C. pneumoniae IgG.
< 1:64 C. psittaci IgG.
The Chlamydia antibody test contains both species- and genus-specific antigens, and serological cross-reactions may be seen in both acute and convalescent samples (less than 1:128). A C. pneumoniae-specific reaction will exhibit titers twofold or greater than titers observed with C. trachomatis or C. psittaci serology. Any IgG titer may indicate past exposure to that particular species. IgG titers in recently infected individuals are typically greater than or equal to 1:512.
The Chlamydia microimmunofluorescent assay slides utilize C. psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. The LGV strains of C. trachomatis are not included in this assay.
Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.
In adult populations, the prevalence of antibody titers indicative of exposure to the organism ranges from 50-78%.
|Component Test Code*||Component Chart Name||LOINC|
|0065104||C. pneumoniae IgG Titer||6913-8|
|0065106||C. trachomatis IgG Titer||6919-5|
|0065107||C. psittaci IgG Titer||6916-1|
- Chlamydia IgG Ab
- CT IgG Ab